CD19 positive
A B-cell surface marker required for anti-CD19 cellular therapy.
Parent marker: CD19
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
CD19 expression is required for anti-CD19 CAR-T therapy and some antibodies. Loss of markers after previous therapy may influence choice.
How this finding appears in a report
Assessed through immunohistochemistry or cell flow in tissue, blood or bone marrow.
When therapy stops working
Loss of CD19 after anti-CD19 therapy includes known mechanisms.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: CD19
CD19 expression is confirmed through pathological examination and is one of the eligibility requirements for anti-CD19 cellular therapy. This examination usually does not stand alone and needs to be read together with other markers.
A negative result does not always mean absent
Summary
- Gen
- CD19
- Variant
- CD19 positive
- Alteration type
- Immunophenotype
- Discussed in
- Lymphoma, Leukemia
- Updated
- 2026-09-10
Other names in reports
CD19+
Drugs discussed
Treatment categories
Related guides
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker CD19
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT05633615Phase 2CAR-T cell therapy
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lymphoma | biomarker: CD19 | CAR-T cell therapy, Immunotherapy, Chemotherapy
United States95 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05633615Not verified
NCT06528301Phase 1Combination regimen
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
United States, Australia9 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06528301Not verified
NCT07532525Phase 1CAR-T cell therapy
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Lymphoma | biomarker: CD19 | CAR-T cell therapy
United States1 registry sites
Why this appears: Appears because it is recorded for Lymphoma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07532525Not verified
NCT05850234Phase 1 / Phase 2CAR-T cell therapy
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Multiple Myeloma | biomarker: CD19 | CAR-T cell therapy, Stem cell transplant
United States34 registry sites
Why this appears: Appears because it is recorded for Multiple Myeloma, it mentions marker CD19, the treatment category is CAR-T cell therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05850234Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- CD19
Biomarker
Reason: Related through a biomarker
- Leukemia
Cancer type
Reason: Related to this page
- Lymphoma
Cancer type
Reason: Related to this page
- Axicabtagene ciloleucel
Drug
Reason: Related to this page
- Blinatumomab
Drug
Reason: Related to this page
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.